Clinical Trial Update: Diclofenac for the Prevention of Post-ERCP Pancreatitis in Higher Risk Patients [Phase 4]

View source ↗

Summary

Phase 4 trial of diclofenac to prevent post-ERCP pancreatitis in high-risk patients was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatitis

Drugs mentioned

• Diclofenac (diclofenac)

Snippet

Sponsor: Queen's University | Conditions: Pancreatitis | Phase 4 | Status: TERMINATED